Ondansetron
- Generic Name
- Ondansetron
- Brand Names
- Zofran, Zuplenz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O
- CAS Number
- 99614-02-5
- Unique Ingredient Identifier
- 4AF302ESOS
- Background
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...
- Indication
In the adult patient population:
i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:
- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum
- Associated Therapies
- -
Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2322
- Registration Number
- NCT00619359
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2017-03-23
- Target Recruit Count
- 1
- Registration Number
- NCT00609765
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
- Conditions
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 710
- Registration Number
- NCT00601172
- Locations
- 🇸🇰
GSK Investigational Site, Poprad, Slovakia
Pharmacotherapy for HIV+ Stimulant Dependent Individuals
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2010-04-14
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 12
- Registration Number
- NCT00599573
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Emory University
- Target Recruit Count
- 64
- Registration Number
- NCT00590317
- Locations
- 🇺🇸
Grady Hospital, Atlanta, Georgia, United States
🇺🇸Grady Memorial Hospital, Atlanta, Georgia, United States
A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 619
- Registration Number
- NCT00539721
A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 37
- Registration Number
- NCT00437229
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2007-02-01
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 120
- Registration Number
- NCT00429832
- Locations
- 🇺🇸
University of New Mexico Hospital Emergency Department, Albuquerque, New Mexico, United States
Ondansetron Reduce Vomiting Associated With Ketamine PSA
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 268
- Registration Number
- NCT00387556
- Locations
- 🇺🇸
The Childrens Hospital, Denver, Colorado, United States
Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
- Conditions
- Interventions
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 150
- Registration Number
- NCT00324467
- Locations
- 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.